cd34 af4117  (R&D Systems)

Journal: bioRxiv

Article Title: THE COMPARATIVE STUDY OF THE EFFECT OF LOW-INTENSITY BROADBAND AND LOW-INTENSITY PULSED ULTRASOUND ON THE AMPUTATIONAL MODEL OF WOUND

doi: 10.64898/2026.04.09.717366

Figure Lengend Snippet: Immunohistochemical tissue staining in rats treated with UMUS on the 14th day from the moment of treatment start. A-Ki-67 in sub-dermal tissue marked with arrows; along collagen thick bunches, fibrocytes are gathered, stained with blue color; some of them are marked as blast forms (arrows); B - VEGF stained structures in both bones and neighboring sub-dermal tissue. C - CD31 in sub-dermal tissue (arrows); D and E - CD34 in bone and sub-dermal tissue, respectively; F-negative control. Calibrate at 100 mcm.

Article Snippet: For the incubation the Abcam antibodies were used: CD31 (EPR17260-254 / ab213175); VEGF (ab100786); Ki67 [SP6] (ab16667), and for CD34 - AF4117 (R&D Systems).

Techniques: Immunohistochemical staining, Staining, Negative Control

Journal: Journal of Neuropathology and Experimental Neurology

Article Title: Angiogenic responses are enhanced by recombinant human erythropoietin in a model of periventricular white matter damage of neonatal rats through EPOR-ERK1 signaling

doi: 10.1093/jnen/nlae001

Figure Lengend Snippet: CD34 + cells/CD34 protein expression was enhanced by active EPOR-ERK1 signaling after hypoxic/ischemic-induced brain injury. (A, B) Immunostaining and quantification of CD34 + cells in rat pups brain. EPO augmented the number of CD34 + cells, while the number was decreased following inhibition of p-ERK1 by U0126. (C) Bar graph and representative western blot images of CD34 protein expression. CD34 protein was upregulated in response to EPO treatment and downregulated following inhibition of p-ERK1 by U0126. *p < 0.05; NS, no significant difference. Scale bar: 100 µm.

Article Snippet: The sections were then incubated overnight at 4°C with a primary antibody for the detection of CD34 (1:1000, AF-4117, R&D), followed by incubation for 2 hours at room temperature with a fluorescein-conjugated anti-IgG secondary detection antibody (1:100, TI-5000, Vector, Newark, CA).

Techniques: Expressing, Immunostaining, Inhibition, Western Blot

Journal: Journal of Neuropathology and Experimental Neurology

Article Title: Angiogenic responses are enhanced by recombinant human erythropoietin in a model of periventricular white matter damage of neonatal rats through EPOR-ERK1 signaling

doi: 10.1093/jnen/nlae001

Figure Lengend Snippet: CD34 + cells/CD34 protein expression was enhanced by active EPOR-ERK1 signaling after hypoxic/ischemic-induced brain injury. (A, B) Immunostaining and quantification of CD34 + cells in rat pups brain. EPO augmented the number of CD34 + cells, while the number was decreased following inhibition of p-ERK1 by U0126. (C) Bar graph and representative western blot images of CD34 protein expression. CD34 protein was upregulated in response to EPO treatment and downregulated following inhibition of p-ERK1 by U0126. *p < 0.05; NS, no significant difference. Scale bar: 100 µm.

Article Snippet: The membranes were then incubated with primary polyclonal antibodies recognizing EPOR (1:1000, FNab02816, Wuhan Fine Biotech, Wuhan, China), p-ERK1 (1:500, ab131438, Abcam, Cambridge, United Kingdom), ERK (1:1000, ab115799, Abcam), and CD34 (1:1000, AF-4117, R&D Systems, Minneapolis, MN) at 4°C overnight.

Techniques: Expressing, Immunostaining, Inhibition, Western Blot